Differential Diagnosis of COVID-19 Enanthema

Coronavirus disease 2019 (COVID-19) is a disease that has become a pandemic in the world with very high transmission rates. COVID-19 is caused by coronavirus which initially infects animals (bats, camels, birds, and anteater). This virus is transmitted by animals to humans, then transmitted from human to human. Coronavirus that infects humans causes acute respiratory distress syndrome (ARDS).[1] [2]

COVID-19 infection begins with the invasion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in host cells. SARS-CoV-2 has a life cycle in host cells to be able to replicate so that viral load will increase and cause symptoms of the disease. The life cycle of SARS-CoV-2 in host cells can be divided into attachment, endocytosis, membrane fusion phases, biosynthesis, and maturation. The presence of SARS-CoV-2 in the host body will trigger a series of immune responses that involve complex intersection signaling.[1] [2] [3] [4]

Transmission of Disease

SARS-CoV-2 is transmitted through saliva by droplet, airborne, and aerosol transmission. Droplets are formed when COVID-19 sufferers talk, cough, or sneeze causing saliva to splash around (± 1 m). SARS-CoV-2 in saliva can last 29 days. SARS-CoV-2 droplet transmission can occur directly or indirectly.[5] [6] Direct droplet transmission occurs when healthy people are splashed with oral fluid when in close contact with an infected patient. Indirect droplet transmission occurs when healthy people touch the patient or the surface of objects or objects around the infected patient. Droplet infectious fluid will evaporate into a lighter fluid and spread through the air (airborne) up to 10 m from the initial location of the droplet. This if inhaled, healthy people become infected. Aerosol transmission is an airborne transmission that occurs indoors and SARS-CoV-2 can last for 3 days in a closed room. Aerosol transmission causes SARS-CoV-2 to infect large numbers of people at one time and in a fast time.[5] [6] [7] [8]

Clinical Manifestations

Symptoms of SARS-CoV-2 infection include an upper respiratory tract infection (URTI) (mild–severe), ARDS, sepsis, and septic shock.[7] Complaint of the oral cavity in COVID-19 patients in the form of mouth and throat pain due to tonsillitis, epiglottitis, or pharyngodynia. SARS-CoV-2 infection also causes inflammation of the nasopharynx region.[9] [10] Complaints of dry mouth and reduced taste sensation occur at a chronic stage. This condition occurs because a high SARS-CoV-2 viral load causes damage to the salivary glands.[11] These complaints can be one indicator of patients suspected of being infected with SARS CoV-2.[9] [10] [11]

In COVID-19 patients, lesions were found in the skin and oral cavity. Skin lesions are exanthem (47%), pseudo-chilblain (erythematous vesicles or erythematous pustules) (19%), urticaria (19%) vesicular eruption (9%), and necrotic (6%).[12] Enanthem is the term exanthem in the oral mucosa.[12] [13] Exanthem is an erythematous rash that develops together with fever or together with a host of other symptoms. Exanthema lesions have morphological variations, including erythematous macules, erythematous papules, erythematous maculopapular, erythematous maculopapular accompanied by petechiae, erythematous vesicles, pustules with erythematous, and urticaria[12] [13] [14] [15] ([Fig. 1] [Table 1]).

Table 1 Differential diagnosis of COVID-19

COVID-19[7] [12]	Hand, foot, and mouth diseases[15] [16]	Measles[15] [16]
Abbreviation: COVID-19, coronavirus disease 2019.
Fever > 38°C Cough Throat pain Nasal congestion Malaise Maculopapular enanthem Skin lesions vary: * Exanthema * Pseudo-chilblain * Urticaria * Necrotic Shortness of breath (moderate–severe symptoms) Pneumonia (severe symptoms)	Fever > 38°C Cough Anorexia Abdominal pain Pain in the throat and oral cavity Vesicular enanthem which ruptures into an ulcer in the mucosa of the tongue, palate Vesicular exanthema on the palms, soles of the feet	Fever > 38°C Cough Conjunctivitis Coryza (runny nose) Koplik’s spot enanthema (white papules with erythematous around them) Exanthema on the skin of the face and neck, which then changes color like copper

Fig. 1 Enanthem lesions on palatal and labial mucosa accompanied by desquamation of gingival patients positive for COVID-19.[12]

Case Management

To reduce pain in the oral cavity and inactivate coronavirus, an antiseptic mouthwash medication containing 0.2% iodine povidone is given. The ability of iodine povidone has been proven in the case of SARS-CoV and Middle East respiratory syndrome coronavirus (MERS CoV).[8] [9] [17] [18] Hydrogen peroxide 1% can be used as an alternative mouthwash, although no specific mechanism is known for deactivating coronavirus.[8] [9] Mouthwash containing chlorhexidine is not effective in COVID-19 cases.[9] Anti-inflammatory mouthwash can be used to reduce pain in the oral cavity,19-23 but the authors have not found a case report journal of this drug used in COVID-19 patients.

Table 2 Anti-inflammatory mouthwash

Content of mouthwash	Work mechanism
Benzydamine HCl 0.15%[19] [20]	Topical anesthetics
Hyaluronic acid[20] [21] [22] [23]	Anti-inflammatory
Zinc[19] [22] [23]	Anti-inflammatory
Tetracycline 0.25%[20]	Anti-inflammatory

Disclosure

History and understanding of clinical characteristics in the initial screening of patients with complaints of the intraoral are the starting points for COVID-19 identification.

• References

• 1 Melo Neto CLM, Bannwart LC, de Melo Moreno AL, Goiato MC. SARS-CoV-2 and dentistry-review. Eur J Dent 2020;14(suppl S1):S130–S139 doi:10.1055/s-0040-1716438
• 2 Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 2020; 10 (02) 102-108
• 3 Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J 2020; 55 (04) 9-11
• 4 Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun 2020;11(1):2251 doi:10.1038/s41467-020-16256-y
• 5 Morawska L, Cao J. Airborne transmission of SARS-CoV-2: the world should face the reality. Environ Int 2020; 139: 105730
• 6 Sabino-Silva R, Jardim ACG, Siqueira WL. Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis. Clin Oral Investig 2020; 24 (04) 1619-1621
• 7 Susilo A, Rumende CM, Pitoyo CW, et al. Coronavirus disease 2019 : review of current literatures. JPDI 2020;7(1):45-67 doi:10.7454/jpdi.v7i1.415
• 8 Ather A, Patel B, Ruparel NB, Diogenes A, Hargreaves KM. Coronavirus disease 19 (COVID-19): Implications for clinical dental care. J Endod 2020; May 46 (05) 584-595
• 9 Meng L, Hua F, Bian Z. Coronavirus disease 2019 (COVID-19): emerging and future challenges for dental and oral medicine. J Dent Res 2020; 99 (05) 481-487
• 10 Lovato A, de Filippis C. Clinical presentation of COVID-19: a systematic review focusing on upper airway symptoms. Ear Nose Throat J 2020; Nov 99 (09) 569-576
• 11 Chen L, Zhao J, Peng J, et al. Detection of SARS-CoV-2 in saliva and characterization of oral symptoms in COVID-19 patients. Cell Prolif 2020;53(12):e12923 doi:10.1111/cpr.12923
• 12 Galván Casas C, Català A, Carretero Hernández G. et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020; 183 (01) 71-77
• 13 Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020; 34 (05) e212-e213
• 14 Drago F, Rampini E, Rebora A. Atypical exanthems: morphology and laboratory investigations may lead to an aetiological diagnosis in about 70% of cases. Br J Dermatol 2002; 147 (02) 255-260
• 15 Drago F, Ciccarese G, Gasparini G. et al. Contemporary infectious exanthems: an update. Future Microbiol 2017; 12 (02) 171-193
• 16 Kadambari S, Segal S, Acute viral exanthems. Medicine 2017;45(12):788-793 doi:10.1016/j.mpmed.2017.09.011
• 17 Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In vitro bactericidal and virucidal efficacy of povidone-iodine gargle/mouthwash against respiratory and oral tract pathogens. Infect Dis Ther 2018; 7 (02) 249-259
• 18 Eggers M. Infectious disease management and control with povidone iodine. Infect Dis Ther 2019; 8 (04) 581-593
• 19 Farah B, Visintini S. Benzydamine for Acute Sore Throat: A Review of Clinical Effectiveness and Guidelines. 2018
• 20 Altenburg A, El-Haj N, Micheli C, Puttkammer M, Abdel-Naser MB, Zouboulis CC. The treatment of chronic recurrent oral aphthous ulcers. Dtsch Arztebl Int 2014; 111 (40) 665-673
• 21 Pignataro L, Marchisio P, Ibba T, Torretta S. Topically administered hyaluronic acid in the upper airway: a narrative review. Int J Immunopathol Pharmacol 2018; 32: 2058738418766739
• 22 Dalessandri D, Zotti F, Laffranchi L. et al. Treatment of recurrent aphthous stomatitis (RAS; aphthae; canker sores) with a barrier forming mouth rinse or topical gel formulation containing hyaluronic acid: a retrospective clinical study. BMC Oral Health 2019; 19 (01) 153
• 23 Mehdipour M, Taghavi A Zenooz, Sohrabi A, Gholizadeh N, Bahramian A, Jamali Z. A comparison of the effect of triamcinolone ointment and mouthwash with or without zinc on the healing process of aphthous stomatitis lesions. J Dent Res Dent Clin Dent Prospect 2016; 10 (02) 87-91

Publication History

Article published online:
26 November 2020